Online citations, reference lists, and bibliographies.
← Back to Search

Nifedipine For Prevention Of Post-ERCP Pancreatitis: A Prospective, Double-blind Randomized Study.

F. Prat, J. Amaris, B. Ducot, M. Bocquentin, J. Fritsch, A. Choury, G. Pelletier, C. Buffet
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Pancreatitis is the most common complication of ERCP. Calcium channel inhibitors have been shown to prevent the development of experimental pancreatitis. The aim of this randomized, placebo-controlled trial was to determine whether the calcium channel blocker nifedipine prevents post-ERCP pancreatitis. METHODS Patients referred for ERCP were enrolled. Those being treated with a calcium channel inhibitor and those with acute or chronic pancreatitis were excluded. Nifedipine or placebo was administered orally less than 3 hours before and within 6 hours after ERCP. The main outcome measure was the number of cases of post-ERCP pancreatitis; a secondary outcome was the rate of post-ERCP pain (without pancreatitis) that persisted for 12 or more hours. RESULTS One hundred fifty-five patients (70 women, 85 men; mean [SD] age 65.8 [18.2] years; range, 23-97 years) were enrolled and randomized to receive nifedipine (76 patients) or placebo (79 patients). The two groups were comparable. Procedures performed were retrograde diagnostic cholangiopancreatography alone (n = 33), biliary sphincterotomy (n = 31), stone extraction (n = 39), stent placement (n = 37), sphincteroplasty (n = 5), and other (n = 3). ERCP was unsuccessful in 5 patients. A single case of severe pancreatitis was observed (placebo group). The rate of post-ERCP pancreatitis was not different between groups (nifedipine, 10 patients, 13.2%; placebo, 14 patients, 17.7%; p = 0.4). The frequency of post-ERCP pain was not different between the groups. The only independent predictor of post-ERCP pancreatitis was difficult cannulation in both groups (OR = 3.78: 95% CI [1.25, 11.45]). CONCLUSION This study failed to demonstrate a significant effect of nifedipine in the prevention of post-ERCP pancreatitis. A multicenter trial with greater statistical power would be needed to demonstrate a benefit for this drug.
This paper references
10.1053/GAST.2001.26047
Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography.
J. Deviére (2001)
10.1159/000201021
Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography.
J. A. Sand (1993)
10.1136/gut.33.8.1129
Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?
K. Binmoeller (1992)
10.1055/S-2007-1001249
Complications of endoscopy.
J. Baillie (1994)
10.1056/NEJM199609263351302
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
G. Cavallini (1996)
10.1016/S0016-5107(00)70377-4
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
A. Andriulli (2000)
10.1136/gut.17.2.127
Hyperamylasaemia after duodenoscopy and retrograde cholangiopancreatography.
G. Skude (1976)
10.1016/S0016-5107(99)70387-1
Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial.
R. Poon (1999)
10.1097/00042737-199805000-00012
Post‐ERCP pancreatitis and hyperamylasaemia: the role of operative and patient factors
R. Dickinson (1998)
10.1111/j.1572-0241.1999.999_u.x
Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study
G. D. Palma (1999)
10.1016/S0016-5107(91)70740-2
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
P. Cotton (1991)
10.1148/RADIOLOGY.156.3.4023241
Acute pancreatitis: prognostic value of CT.
E. Balthazar (1985)
10.1016/0016-5085(88)90182-5
Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia.
M. Guelrud (1988)
10.1016/S0016-5107(99)70385-8
Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group.
M. Freeman (1999)
10.1056/NEJM199609263351302
Gabexate mesilate for the prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography.
G. Cavallini (1996)
10.1056/NEJM199609263351309
Complications of endoscopic sphincterotomy and their prevention.
K. Huibregtse (1996)
10.1097/00042737-199306000-00013
Verapamil is beneficial in a model of post‐ERCP pancreatitis
A. Leahy (1993)
10.1056/NEJM199609263351301
Complications of endoscopic biliary sphincterotomy.
M. Freeman (1996)
10.1055/S-2007-1001308
Predictors of post-ERCP complications in patients with suspected choledocholithiasis.
S. Mehta (1998)
10.1097/00000658-197905000-00016
The Timing of Biliary Surgery in Acute Pancreatitis
John H. C. Ranson (1979)
10.1056/NEJM198901123200203
The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction.
J. Geenen (1989)
10.1016/0016-5085(91)90735-4
Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts.
S. Sherman (1991)



This paper is referenced by
10.1159/000108956
Nitric Oxide Pathways and Evidence-Based Perturbations in Acute Pancreatitis
M. DiMagno (2007)
10.1053/GE.2003.V57.AMGE030576633
Complications of ERCP.
J. Mallery (2003)
10.1097/MPA.0b013e31817f528f
Preventive Effects of Ulinastatin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-Risk Patients: A Prospective, Randomized, Placebo-Controlled Trial
J. Yoo (2008)
10.1016/J.GIEC.2006.11.002
Minimizing complications in endoscopic retrograde cholangiopancreatography and sphincterotomy.
Jeremy S Rochester (2007)
10.1159/000258373
Prevention of ERCP-Induced Pancreatitis
G. Manes (2010)
10.4172/pharmaceutical-sciences.1000383
Effects of Calcium Channel Blockers on Trypsinogen Activation and Severity of Cerulein-induced Acute Pancreatitis in Rats
A. B. Uyumlu (2018)
10.1080/03639040500271852
Identification of Photoproducts of Hexahydroquinoline Derivatives by GC-EI-MS and HPLC-ESI-MS
J. Mielcarek (2005)
Acute pancreatitis – the most common complication after endoscopic retrograde cholangiopancreatography
Laura Maðalaitë (2008)
10.4253/wjge.v2.i5.165
Endoscopic retrograde cholangiopancreatography associated pancreatitis: A 15-year review.
Kevin E. Woods (2010)
10.1097/MPA.0b013e3182152eb6
Intravenous Synthetic Secretin Reduces the Incidence of Pancreatitis Induced by Endoscopic Retrograde Cholangiopancreatography
P. Jowell (2011)
10.1111/j.1440-1746.2006.04085.x
Ulinastatin shows preventive effect on post‐endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study
H. Fujishiro (2006)
10.1016/S0016-5107(04)00353-0
Prevention of post-ERCP pancreatitis: a comprehensive review.
M. Freeman (2004)
10.1097/mpa.0b013e318120023a
Hereditary Pancreatitis Amlodipine Trial: A Pilot Study of a Calcium-Channel Blocker in Hereditary Pancreatitis
V. Morinville (2007)
10.1016/J.COPH.2005.06.007
Pharmacological management of pancreatitis.
W. Hoogerwerf (2005)
10.1097/MCG.0b013e3181eb600e
A Randomized Controlled Trial of Valdecoxib and Glyceryl Trinitrate for the Prevention of Post-ERCP Pancreatitis
V. Bhatia (2011)
10.1097/MPA.0b013e31816857e3
Meta-Analysis of Prophylactic Allopurinol Use in Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
M. Zheng (2008)
10.1111/j.1572-0241.2006.00959.x
Effect of Octreotide Administration in the Prophylaxis of Post-ERCP Pancreatitis and Hyperamylasemia: A Multicenter, Placebo-Controlled, Randomized Clinical Trial
Z. Li (2007)
10.1136/gut.2007.121657
Guidelines on the management of common bile duct stones (CBDS)
E. Williams (2008)
10.1007/s11894-020-00796-w
Emerging Therapies to Prevent Post-ERCP Pancreatitis
N. Thiruvengadam (2020)
10.1016/J.GTC.2007.03.006
Incidence, risk factors, and prevention of post-ERCP pancreatitis.
S. Cooper (2007)
10.1016/j.curtheres.2008.08.001
Gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis update.
Minghua Zheng (2008)
10.1002/14651858.CD004890.PUB2
Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones.
B. Weinberg (2006)
10.1159/000279306
Effects of Medications on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
N. Li (2010)
10.1136/gut.52.12.1768
Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial
R. Poon (2003)
10.1055/s-0029-1244208
European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis.
J-M Dumonceau (2010)
Antiproteases in preventing post-ERCP acute pancreatitis.
T. Tsujino (2007)
10.1016/S0210-5691(03)79922-7
Esfinterostomía y colangiopancreatografía retrógrada endoscópica en la pancreatitis aguda: terapéutica y profilaxis
M. V. D. L. T. Prados (2003)
10.1007/S11894-004-0045-Y
Endoscopic papillotomy, syn. sphincterotomy: Results from the past two years
M. Classen (2004)
10.1016/S0016-5107(04)02647-1
High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial.
P. Katsinelos (2005)
10.1111/j.1572-0241.2006.00950.x
Pharmacotherapy for the Prevention of Post-ERCP Pancreatitis
Erina N. Foster (2007)
10.1097/MOG.0b013e3283528e68
Post-ERCP pancreatitis: review of current preventive strategies
Matthew E. Feurer (2012)
10.4103/ejim.ejim_13_19
Efficacy of chymotrypsin in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis
A. Attia (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar